⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
prnewswire.com
LLY
INCY
SkinnyRx GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Program, Pricing, and FDA Regulatory Status Examined
globenewswire.com
ELAN
LLY
NVO
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight
prnewswire.com
LLY
Fourteen Morgan & Morgan Attorneys Recognized by Lawdragon as Leading Plaintiff Consumer Lawyers
globenewswire.com
GOOGL
META
LLY
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race
globenewswire.com
MDBH
LLY
NVO
PFE
AZN
GILD
GPCR
insitro Appoints Joe Hand as Chief People Officer to Advance Talent Strategy for Next Stage of Development
businesswire.com
AMGN
LLY
GILD
OTF + Lilly Collaboration Update on Registration Response | OMA QI Scaling Initiative Gains National Response, Bringing Together Diverse Practice Types Across 39 States Ready to Announce with Confidence?
newsfilecorp.com
LLY
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
globenewswire.com
LLY
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
prnewswire.com
LLY
Tinnitus Treatment Landscape Set for Significant Market Upswing During Forecast Period (2026-2036) as Need for Effective Therapies Intensifies | DelveInsight
prnewswire.com
SPRC
REGN
LLY